Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
AVI, Tekmira Land Defense Contracts
by Rick Mullin
July 26, 2010
| A version of this story appeared in
Volume 88, Issue 30
AVI BioPharma has been awarded a contract for up to $291 million from the Department of Defense’s Chemical & Biological Defense Program to develop its hemorrhagic fever virus drug candidates, as well as treatments for Ebola and Marburg viruses. DOD will pay $80 million for the first phase of the project, which is expected to last 18 months. Meanwhile, Canada’s Tekmira Pharmaceuticals won a contract with CBDP to develop an RNA interference therapy to treat Ebola virus infection. The firm is eligible to receive up to $34.7 million over the next three years. Total funding could reach $140 million.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter